Three new drugs available to fight kidney cancer.
Bankhead
Charles
C
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D018572:Disease-Free Survival; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy*; D000077341:Lapatinib; D015337:Multicenter Studies as Topic; D010982:Platelet-Derived Growth Factor / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011758:Pyrroles / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077210:Sunitinib; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects
D000970:Antineoplastic Agents; D007211:Indoles; D016898:Interferon-alpha; D010982:Platelet-Derived Growth Factor; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D011799:Quinazolines; D042461:Vascular Endothelial Growth Factor A; D000077341:Lapatinib; C401859:temsirolimus; D011505:Protein-Tyrosine Kinases; D000077210:Sunitinib; D020123:Sirolimus